These macro-level (mg/mL scale) changes in blood plasma glycan biochemistry are thought to be mediated, at least in part, by cytokines secreted from the tumor which are recognized by the liver and/or immune system as part of a systemic inflammatory response, altering the way that these two major glycoprotein-producing systems glycosylate their proteins [33–38]. The gene discussed is ART4; the disease is neoplasm.